Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer
Completed · Phase 2
Conditions studied: Kidney Cancer
In brief
RATIONALE: Tretinoin may help cells that are involved in the body's immune response to work better. Interleukin-2 may stimulate the white blood cells to kill kidney cancer cells. Giving tretinoin together with interleukin-2 may kill more tumor cells. PURPOSE: This randomized phase II trial is studying how well giving three different doses of tretinoin together with interleukin-2 works in treating patients with stage IV kidney cancer.
Key facts
- Study ID
- NCT00100906
- Run by
- H. Lee Moffitt Cancer Center and Research Institute
- People needed
- 18
- Starts
- 2004-08-01
- Expected to finish
- 2013-07-01
- Last updated by the study team
- 2013-08-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.